GW Pharmaceuticals PLC- (NASDAQ:GWPH) Director Sells $53,640.00 in Stock

GW Pharmaceuticals PLC- (NASDAQ:GWPH) Director William A. Waldegrave sold 3,576 shares of the business’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $15.00, for a total transaction of $53,640.00. Following the completion of the sale, the director now owns 3,576 shares of the company’s stock, valued at approximately $53,640. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

NASDAQ GWPH opened at $172.45 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.81 and a quick ratio of 7.19. The stock’s 50 day moving average price is $174.62. GW Pharmaceuticals PLC- has a 52 week low of $90.14 and a 52 week high of $196.00.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($1.68) EPS for the quarter, topping the consensus estimate of ($2.48) by $0.80. The firm had revenue of $39.20 million during the quarter, compared to analyst estimates of $12.32 million. GW Pharmaceuticals PLC- had a negative net margin of 458.79% and a negative return on equity of 45.75%. GW Pharmaceuticals PLC-‘s revenue was up 1189.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($3.12) EPS. Research analysts forecast that GW Pharmaceuticals PLC- will post -4.76 earnings per share for the current fiscal year.

GWPH has been the subject of several recent research reports. ValuEngine upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, May 17th. CIBC boosted their price target on shares of Stella-Jones from C$51.00 to C$53.00 in a report on Tuesday, May 7th. Morgan Stanley restated a “buy” rating on shares of GW Pharmaceuticals PLC- in a report on Tuesday, April 9th. BidaskClub lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, June 26th. Finally, JPMorgan Chase & Co. boosted their price target on shares of LYFT from $82.00 to $86.00 in a report on Wednesday, May 8th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company’s stock. GW Pharmaceuticals PLC- currently has an average rating of “Buy” and an average target price of $205.40.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. US Bancorp DE raised its stake in shares of GW Pharmaceuticals PLC- by 0.6% during the 1st quarter. US Bancorp DE now owns 11,683 shares of the biopharmaceutical company’s stock worth $1,969,000 after acquiring an additional 75 shares in the last quarter. Oppenheimer Asset Management Inc. raised its stake in shares of GW Pharmaceuticals PLC- by 14.9% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 601 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 78 shares in the last quarter. Brandywine Oak Private Wealth LLC raised its stake in shares of GW Pharmaceuticals PLC- by 6.0% during the 1st quarter. Brandywine Oak Private Wealth LLC now owns 1,435 shares of the biopharmaceutical company’s stock worth $241,000 after acquiring an additional 81 shares in the last quarter. Belpointe Asset Management LLC raised its stake in shares of GW Pharmaceuticals PLC- by 6.2% during the 4th quarter. Belpointe Asset Management LLC now owns 1,463 shares of the biopharmaceutical company’s stock worth $142,000 after acquiring an additional 85 shares in the last quarter. Finally, Advisory Services Network LLC raised its stake in shares of GW Pharmaceuticals PLC- by 23.1% during the 4th quarter. Advisory Services Network LLC now owns 511 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 96 shares in the last quarter. Hedge funds and other institutional investors own 78.91% of the company’s stock.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Featured Article: Balance Sheet

Insider Buying and Selling by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.